Evidence map›Paper›PMID 30609252›Full record

ReviewPediatric pulmonology2019

Can early intervention in pediatric asthma improve long-term outcomes? A question that needs an answer.

Miguel J Lanz, Ileen Gilbert, Stanley J Szefler, Kevin R Murphy

Open access · hybridAbstract readReview
In one paragraph

Review in Pediatric pulmonology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Managing childhood asthma with an eye toward environmental, social, and behavioral features.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Miguel J LanzAllergy and Asthma, AAADRS Clinical Research Center, Coral Gables, Florida.ORCID 0000-0002-2868-5596
Ileen GilbertAstraZeneca, Wilmington, Delaware.
Stanley J SzeflerThe Breathing Institute, Children's Hospital Colorado and Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Kevin R MurphyBoys Town National Research Hospital, Omaha, Nebraska.
Allergy, Asthma and Clinical Research Center · USAstraZeneca (United States) · USBoys Town National Research Hospital · USChildren's Hospital Colorado · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough many children with asthma do not experience persistence into adulthood, recent studies have suggested that poorly controlled asthma in childhood may be associated with significant airflow obstruction in adulthood. However, data regarding disease progression are lacking, and clinicians are not yet able to predict the course of a child's asthma. The goal of this article was to assess the current understanding of childhood asthma treatment and progression and to highlight gaps in information that remain. DATA SOURCES: Nonsystematic PubMed literature search and authors' expertise. STUDY SELECTION: Articles were selected at the authors' discretion based on areas of interest in childhood asthma treatment and progression into adulthood.

resultsUncontrolled asthma in early childhood can potentially have lasting effects on lung development, but it is unclear whether traditional interventions in very young children preserve lung function. Although not all children respond to standard interventions, certain asthma phenotypes have been identified that can help to understand which children may respond to a particular treatment.

conclusionClinicians should monitor children's asthma control and pulmonary function over time to assess the long-term impact of an intervention and to minimize the effect of uncontrolled asthma, especially exacerbations, on lung development. New biologic therapies have shown promise in treating adults with severe, uncontrolled asthma, and some of these therapies are approved in the United States for children as young as age 6. However, knowledge gaps regarding the efficacy and safety of these treatments in younger children hamper our understanding of their effect on long-term outcomes.

Indexed as

Adrenal Cortex HormonesAnti-Asthmatic AgentsAsthmaBiological ProductsChildChild DevelopmentDisease ProgressionHumansLungPhenotypeTreatment OutcomeAdrenal Cortex HormonesAnti-Asthmatic AgentsBiological Productsbiologicbiomarkerschildhoodprogression

Identifiers

PMID30609252
PMCPMC6590791
OpenAlexW2908384926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.